Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
University Hospital and University of Basel
& Sixto-Leal, C
, 43 , 869-874, doi: Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A
In the primary trial assessing 14,068 individuals receiving semaglutide versus 13,154 propensity score-matched individuals receiving empagliflozin, the incidence of the primary outcome was 1.9% versus 2.2% at 1 year, 3.7% versus 4.5% at 2 years, and 5.9% versus 6.9% at 3 years for the semaglutide-treated and empagliflozin-treated groups, respectively
The theoretical efficacy concern grows here, dropping to roughly 75% of standard dosing based on modeling
US$ 23.60
US$ 25.28
US$ 26.32
